News Galapagos drops plan to split after 'market developments' Shortly after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Galapagos has had a change of heart.
News Galapagos unveils plan to split, hiving off its drugs unit Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.
News Paul Stoffels swiftly resurfaces as Galapagos' next CEO Paul Stoffels' retirement at the end of last year after nine years as head of R&D at Johnson & Johnson was short lived – he's just been named chef executive of Galapagos.
News J&J's long-serving R&D chief Paul Stoffels announces retirem... Paul Stoffels is bringing a nine-year tenure as head of R&D at Johnson & Johnson to a close, announcing plans to retire at the end of the year.
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face